Transcell Oncologics bagged ownership rights on USPTO granted Intellectual Property on a technology developed simulating Off-Shelf CAR T cell therapy for cancers.
Published Date: November 29th 2019
Transcell Oncologics bagged ownership rights on USPTO granted Intellectual Property on a technology developed simulating Off-Shelf CAR T cell therapy for cancers.
CAR T Therapy is a form of cell-based immunotherapy that utilizes individually transformed T cells that are a part of the human immune system — combating debilitating cancer. Currently, CAR T-cell therapy is FDA approved (autologous)for patients with relapsed or refractory acute lymphoblastic leukaemia up to age 25 and as the standard of care only for few forms of aggressive, refractory non-Hodgkin lymphoma (blood cancer types) for now. Currently, it is a bespoke product made for individual patients, therefore the time is taken from evaluation, enrolment of the patient, manufacture CARs till re-infusion can preclude access, as the costs involved as against any Off-shelf kind of presentation. Also, the T cells used as a raw starting material from cancer patients would have cancer-associated T cell dysfunction (unless proven otherwise) while being not eligible for CARs!! associated with life-threatening adverse effects.
An ideal CAR T cell therapy would be definitely Off-shelf and allogenic not just for ease of access and rationale of medical application but with affordability which is the biggest concern for countries like India with 90% of the cancer patients prefer death to bear treatment costs.
About the Intellectual Property (IP):
The present invention recommends a new approach of allogenic dendritic-stem cell vaccine platform for clinical application. It proposes the abundant human biological discard as allogenic (biobank derived) source for dendritic special type and mesenchymal stem cells equilibrated package for production of CARs. The individual roles of dendritic cells and mesenchymal stem cells in immunomodulation is exploited in developing this new combinatorial platform of cellular vectors for the targeted killing of tumour cells in the patient’s body.
The Mesendron technology developed is Off shelf in true sense with capabilities to address:
Rejection, GVHD, healthy T cell population (dysfunction, ease of access, reduced time reaching patient
Treatment costs, Harvest and Manufacturing difficulties associated with ambiguity, Product variability
The biobank source in manufacturing CARs will remove the requirement for repeated donations by healthy volunteers and the Mesendron technology creates a bank of HLA neutral CARs as Off shelf products revolutionizing both the application strategy and integrated domains.
This IP agreeably aligns with the Company’s vision and mission to translate the power of adult (stem) cell technologies to cancer clinical reality through chemical space, cellular and vector platforms as cure options.
A 
COMPLETELY NEW & PRACTICAL PERSPECTIVE ON CAR T CELL TECHNOLOGY
NEXT GENERATION WITH A SCOPE TO REVOLUTIONIZE AFFORDABILITY AND ACCESS TO NEEDY PATIENTS